Cerebral Ischemia Clinical Trial
Official title:
Inhalative Stickstoffmonoxid (NO) Behandlung Bei Patienten Mit Schwerem, therapierefraktärem Zerebralen Vasospasmus Nach Subarachnoidalblutung
Aneurysmal subarachnoid haemorrhage (aSAH) is a rare but severe subtype of stroke with high mortality and morbidity. Besides rebleeding, delayed cerebral ischaemia and cerebral vasospasm (CVS) are thought to be major reasons for the poor outcome in survivors of aSAH. Despite advances in the detection and treatment of CVS 20-40% of CVS patients experience cerebral Ischaemia. Experimental animal studies for ischaemic stroke, traumatic brain injury, and SAH showed that inhaled nitric oxide (iNO) selectively dilates cerebral arteries and arterioles in hypoperfused brain tissue. The investigators therefore performed this prospective pilot study to evaluate the effects of iNO on cerebral perfusion in patients with refractory vasospasm after aSAH.
Aneurysmal subarachnoid haemorrhage (aSAH) is a rare but severe subtype of stroke with high mortality and morbidity. Besides rebleeding, delayed cerebral ischaemia and cerebral vasospasm (CVS) are thought to be major reasons for the poor outcome in survivors of aSAH. CVS, thought to be caused by blood breakdown products, peak in the second week after hemorrhage and affect up 88% of patients with severe aSAH. Despite advances in the detection and treatment of CVS there is no established therapy and up 40% of patients experience cerebral ischemia. In symptomatic vasospasm and cerebral hypoperfusion various treatments like induced hypertension, angioplasty and intraarterial vasodilators are used as rescue therapies. Yet, their effect is not proven. In recent experimental studies, inhaled nitric oxide (iNO) has been shown to induce a selective dilation of cerebral arteries and arterioles in hypoperfused brain tissue [8, 9]. After experimental SAH in mice, iNO significantly reduced the number and severity of SAH-induced spasms of cerebral microvessels, thereby improving cerebral perfusion. Inhaled NO has regulatory approval in man by the Food and Drug Administration (FDA) and by the European Medicines Agency (EMA) for the treatment of several pulmonary pathologies. At first the efficacy of iNO was thought to be limited to the lungs but, based on the results of the experimental studies the investigators hypothesised that iNO may relieve CVS and improve cerebral perfusion in patients with aSAH. The investigators performed this prospective trial to evaluate the effect of iNO on cerebral perfusion in patients with severe refractory CVS. Only patients with refractory CVS after maximum conservative treatment were included. Inhaled NO was administered to a maximum dose of 40ppm. The effect was assessed by digital subtraction angiography (DSA), tissue oxygen partial pressure (PtiO2), transcranial Doppler (TCD), and CT perfusion (CTP) imaging. Patiente outcome is assessed at 12 weeks an 6 months after hemorrhage and included NIHSS, Mini Mental State (MMS) test, and modified Rankin Scale (mRS). ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
Recruiting |
NCT04167527 -
Endovascular Therapy for Low NIHSS Ischemic Strokes
|
Phase 2/Phase 3 | |
Recruiting |
NCT04583163 -
Variability in Transcranial Doppler Technique in Neuro-Critical Care Patients
|
||
Completed |
NCT01436812 -
Effect of Positive End Expiratory Pressure (PEEP) on Cerebral Oxymetry During Laparoscopy
|
N/A | |
Terminated |
NCT00141011 -
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
|
Phase 3 | |
Recruiting |
NCT05053932 -
Long-term Comparative Cerebrovascular Outcome After Transplantation vs Standard Care in Sickle Cell Anemia
|
||
Completed |
NCT04437862 -
A Study to Evaluate the Q Revascularization System for Neurointervention in Acute Ischemic Stroke
|
N/A | |
Completed |
NCT00598819 -
A Prospective Study of a New Device for Monitoring Cerebral Oxygenation on Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00207961 -
The Threshold Value of Regional Cerebral Oxygenation in Detecting Cerebral Ischemia
|
N/A | |
Not yet recruiting |
NCT04696523 -
Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage
|
Phase 2 | |
Completed |
NCT02351518 -
Cerebral Autoregulation and Vasospasm in Patients With TBI
|
||
Completed |
NCT01546636 -
The Effect of Ventilation on Cerebral Oxygenation in the Sitting Position
|
N/A | |
Completed |
NCT04047563 -
Efficacy of Sovateltide (PMZ-1620) in Patients of Acute Ischemic Stroke
|
Phase 3 | |
Completed |
NCT05087836 -
Correlation of Cerebral Oxygen Saturation Measured From 2 Sensor Sites: Forehead vs. Temporal
|
||
Completed |
NCT02448069 -
Safety and Feasibility of Argatroban, Tissue Plasminogen Activator and Intra-arterial Therapy in Stroke
|
Phase 2 | |
Completed |
NCT02147275 -
Monitoring Hypertensive Patients's Cerebral Oxygen Saturation
|
N/A | |
Completed |
NCT01875055 -
Reversing Cerebral Oxygen Desaturations Greater That 10% of Baseline Values Using NIRS in the ICU
|
N/A | |
Completed |
NCT02389647 -
Identification of Novel Molecular Markers for Cerebral Ischemia From Patients With Minor and Devastating Ischemic Injury
|
||
Completed |
NCT02643030 -
Hypercapnia During Shoulder Arthroscopy
|
N/A | |
Completed |
NCT01436799 -
Desflurane Versus Propofol in the Sitting Position
|
N/A |